RankAlpha logo
Back to Rankings

AURA

Aura BiosciencesA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Primary-source disclosures support a real clinical calendar: mid-2026 NMIBC data, mid-2026 CoMpass enrollment completion, additional 2026 proof-of-concept updates, and a defined 2H 2027 pivotal readout path, while cash of $144.2 million was said to fund operations into Q1 2027 [#8-K-2026-03-30].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -5.2.
What can break
Cash runway into Q1 2027 may tighten if trial costs rise or timelines slip.
Momentum
79
Value
41
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $14.00 · Bear $3.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $20.20
Why
Momentum79 · Δ7d -5.2
Value41 · Δ7d +0.1
Sentiment67 · Δ7d +9.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
79
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.2
Δ21d
-12.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
67
33% active weight
Current posture
7d trendImproving
Δ7d
+9.5
Δ21d
+22.2
Why this grade

Composite grade A. Momentum 79.2 / Value 41.1 / Sentiment 67.2

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$743.35M
Beta
0.46
Shares Out
63.5M
P/E (TTM) · Derived
-6.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.38
Rev YoY
-
EPS YoY
+6.5%
Gross Margin
-
Op Margin
-
Net Debt
-$151.09M
Current Ratio
9.04
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology